Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer

Sponsor
Rigshospitalet, Denmark (Other)
Overall Status
Completed
CT.gov ID
NCT05698667
Collaborator
The Novo Nordic Foundation (Other)
26
1
1
7
3.7

Study Details

Study Description

Brief Summary

The aim of the study was to examine the detection rate and tumor size evaluation in patients with suspected oropharynx cancer using a new technique with transoral ultrasound of the oropharynx. The new technique was compared to Magnetic Resonance Imaging (MRI). The study investigators included patients referred to a tertiary head & neck cancer center in Copenhagen, Denmark, with suspicion of oropharynx cancer. Patients supplied written informed consent and were included and ultrasound scanned with local anesthesia in the outpatient clinic. Blinded assessment of MRI's was performed for tumor detection and compared to ultrasound with the reference standard being histopathology biopsy results.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Transoral ultrasound
  • Diagnostic Test: Transcervical ultrasound
N/A

Detailed Description

An explorative diagnostic study was performed at the Department of Otorhinolaryngology, Head & Neck Surgery, Copenhagen University Hospital - Rigshospitalet, Denmark from October 1st, 2021, to April 30th, 2022. The study investigators invited adult patients from the outpatient cancer clinic referred with a suspicion of oropharynx cancer to participate in the study. At the study investigators' center, all head & neck cancer patients receive diagnostic work-up which includes clinical exam, flexible laryngoscopy with narrow-band imaging, surgeon-performed neck ultrasound and biopsy and/or cytology with same-day results. Patients were enrolled after verbal and written consent and were offered an ultrasound examination of the oropharynx as an addition to the standard diagnostic workup in the outpatient clinic. All included patients also received an MRI of the head and neck. Clinical data including age, sex, smoking habits, alcohol consumption, date of MRI scan, and histopathology results were obtained from medical charts after inclusion.

Interventions included transoral ultrasound of the tonsils and base of tongue, conducted with BK5000 ultrasound machines using the X18L5s "hockey stick" transducer. Transcervical ultrasound was also performed in patients where a tongue base cancer was most likely. Standard linear neck transducers (X18L5) or a curved 9C2 transducer was used. The tonsils and tongue base were scanned in two planes if possible, and doppler flow was recorded as well. Ultrasound images were stored as video clips.

The detection of tumors with ultrasound was recorded as "positive" if a well-defined tumor was seen that was clearly visualized compared to the contralateral side. A "negative" result was given if no tumors were suspected on either side. An "inconclusive" result was given if a tumor was not clear, but there was suspicious asymmetry visualized. The anatomical sub-location of tumors were stratified into right and left tonsil, tongue base, overlapping tonsil and tongue base, and "other" sub-locations. "Other" sub-locations included the soft palate, uvula, oropharynx posterior wall, vallecula, anterior pharyngeal arch and posterior pharyngeal arch.

MRI was used as the reference test. An expert neuroradiologist blinded to ultrasound results and histopathology rated all tests for tumor detection in the oropharynx and tumor size in detected tumors.

Statistical analysis:

Tumor detection of oropharynx ultrasound and MRI will be compared using the histopathologic diagnosis (cancer or benign) as reference standard to calculate sensitivity, specificity, positive- and negative predictive values (PPV, NPV).

Inconclusive tests will be analyzed as a positive result due to the clinical consequences often leading to diagnostic tonsillectomy.

McNemar's test for differences between sensitivity, specificity, PPV and NPV between ultrasound and MRI will be calculated.

The greatest tumor diameter will be compared between ultrasound and MRI using scatter plots and the Pearson's R correlation coefficient. Tumor volumes calculated using the formula for an ellipse: π/6 * craniocaudal * anteroposterior * mediolateral will be compared. Statistical analysis will be performed using R software version 4.2.2.

Study Design

Study Type:
Interventional
Actual Enrollment :
26 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Surgeon-performed Outpatient Transoral and Transcervical Ultrasound for the Diagnostic Work-up of Oropharynx Cancer: a Feasibility Study
Actual Study Start Date :
Oct 1, 2021
Actual Primary Completion Date :
May 1, 2022
Actual Study Completion Date :
May 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Oropharynx Ultrasound

Transoral and transcervical ultrasound of the oropharynx, including the tonsils and tongue base.

Diagnostic Test: Transoral ultrasound
Under local anesthetic with xylocaine spray in the oropharynx, the tonsils and tongue base are scanned with small-footprint, high-frequency ultrasound transducers (such as the 18XL5s hockey-stick from BK Medical)

Diagnostic Test: Transcervical ultrasound
The tongue base and tonsils are scanned externally via the neck, where a (preferably low-frequency) transducer is placed onto the skin above the hyoid bone to visualize the tongue base. The tonsils are visualized adjacent to the tongue base on either side and are located deep to the submandibular glands in a oblique coronal plane.

Outcome Measures

Primary Outcome Measures

  1. Proportion of patients with oropharynx cancer detected by ultrasound compared to MRI [Within two weeks.]

    Patients with cancer (histopathology verified) correctly detected by a positive ultrasound or MRI test result.

Secondary Outcome Measures

  1. Greatest tumor diameter compared between ultrasound and MRI. [1 day]

    Greatest tumor diameter measured in millimeters.

  2. Proportion of patients without oropharynx cancer detected by ultrasound compared to MRI [Within three months.]

    Patients with benign tonsillar asymmetry (histopathology verified) correctly detected by a negative ultrasound or MRI test result.

  3. Tumor volume compared between ultrasound and MRI [1 day]

    Tumor volume calculated as an ellipsoid in cubic mm.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria (any of the following):
  • Visible and/or palpable tumor or asymmetry of the tonsils, tongue base or oropharynx.

  • Subjective symptoms of oropharynx cancer including dysphagia, odynophagia and/or referred otalgia.

Exclusion Criteria:
  • Unable to understand Danish or English.

  • Unable to provide written informed consent.

  • Age younger than 18 years.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Otorhinolaryngology, Head & Neck Surgery & Audiology Copenhagen Denmark 2100

Sponsors and Collaborators

  • Rigshospitalet, Denmark
  • The Novo Nordic Foundation

Investigators

  • Study Director: Tobias Todsen, MD, PhD, Rigshospitalet, Denmark

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Martin Garset-Zamani, MD, Principal Investigator, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT05698667
Other Study ID Numbers:
  • Transoral US Feasibility
First Posted:
Jan 26, 2023
Last Update Posted:
Feb 1, 2023
Last Verified:
Jan 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 1, 2023